Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536198 · ClinicalTrials.gov registry record · Phase 4
Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
A Phase 4 study of Premenstrual Dysphoric Disorder, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 252
- Enrollment target
- 3
- Study locations
NCT00536198 is a Phase 4 study of Premenstrual Dysphoric Disorder that has completed, run by Yale University. The registered enrollment target is 252 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT00536198, a Phase 4 study of Premenstrual Dysphoric Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 252 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate the effectiveness of sertraline in reducing symptoms in women diagnosed with premenstrual dysphoric disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sertraline
Study Locations (3)
Connecticut
- Yale University School of Medicine - New Haven
New York
- Cornell University, Weill Medical College - New York
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2007-11-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536198
The ClinicalTrials.gov registry entry for NCT00536198 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Premenstrual Dysphoric Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00536198 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, New York, Virginia.
Frequently Asked Questions
What is clinical trial NCT00536198 about?
NCT00536198 is a clinical study titled "Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder". This study will evaluate the effectiveness of sertraline in reducing symptoms in women diagnosed with premenstrual dysphoric disorder.
What is the current status of trial NCT00536198?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 252 participants. The study started on 2007-11-06. Estimated completion is 2012-02.
What conditions does trial NCT00536198 study?
This clinical trial studies the following conditions: Premenstrual Dysphoric Disorder.
What interventions are being tested in trial NCT00536198?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT00536198?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00536198 being conducted?
This trial has 3 study locations across Connecticut, New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premenstrual Dysphoric Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.